Cazac-Panaite, G.-D.; Lăcătușu, C.-M.; Grigorescu, E.-D.; Foșălău, A.-B.; Onofriescu, A.; Mihai, B.-M.
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis. J. Clin. Med. 2025, 14, 1042.
https://doi.org/10.3390/jcm14041042
AMA Style
Cazac-Panaite G-D, Lăcătușu C-M, Grigorescu E-D, Foșălău A-B, Onofriescu A, Mihai B-M.
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis. Journal of Clinical Medicine. 2025; 14(4):1042.
https://doi.org/10.3390/jcm14041042
Chicago/Turabian Style
Cazac-Panaite, Georgiana-Diana, Cristina-Mihaela Lăcătușu, Elena-Daniela Grigorescu, Adina-Bianca Foșălău, Alina Onofriescu, and Bogdan-Mircea Mihai.
2025. "Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis" Journal of Clinical Medicine 14, no. 4: 1042.
https://doi.org/10.3390/jcm14041042
APA Style
Cazac-Panaite, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B.-M.
(2025). Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis. Journal of Clinical Medicine, 14(4), 1042.
https://doi.org/10.3390/jcm14041042
